胆囊癌伴结肠系膜、大网膜、结肠转移漏诊1例报告
A Case Report of Missed Diagnosis of Gallbladder Carcinoma with Colonic Mesocolon, Omentum and Colon Metastasis
DOI: 10.12677/ACM.2022.12111441, PDF, HTML, XML, 下载: 202  浏览: 325 
作者: 李 哲:大理大学临床医学院,云南 大理;谭云波, 金礼权*:大理大学第一附属医院普外一科,云南 大理
关键词: 胆囊癌转移漏诊Gallbladder Cancer Metastasis Missed Diagnosis
摘要: 胆囊癌是一种胆道的恶性肿瘤,起源于胆囊黏膜,发病较隐匿。胆囊癌的早期发展通常是无症状的,也具有较高的转移扩散倾向,因此诊断较晚,预后极差,手术切除率较低,对放化疗治疗不敏感。在全球的发病率也不同,比如在发达国家中并不常见,但其在发展中国家的某些地区很常见。因此,漏诊率、误诊率也是影响胆囊癌诊治的主要问题。尽管胆囊癌发病率较低,但其死亡率较高。
Abstract: Gallbladder cancer is a malignant tumor of the biliary tract, which originates from the gallbladder mucosa and has a hidden incidence. The early development of gallbladder cancer is usually asymp-tomatic, and it also has a high tendency of metastasis and diffusion, so the diagnosis is late, the re-section rate is low and the prognosis is very poor, it is insensitive to radiotherapy and chemothera-py. The global incidence rate is also different. For example, it is not common in developed countries, but it is common in some parts of developing countries. Therefore, the rate of missed diagnosis and misdiagnosis is also the main problem affecting the diagnosis and treatment of gallbladder cancer. Although the incidence rate of gallbladder cancer is low, its mortality is high.
文章引用:李哲, 谭云波, 金礼权. 胆囊癌伴结肠系膜、大网膜、结肠转移漏诊1例报告[J]. 临床医学进展, 2022, 12(11): 9998-10002. https://doi.org/10.12677/ACM.2022.12111441

1. 引言

胆囊癌是一种相对罕见的恶性肿瘤,发病率约占世界所有肿瘤的1.2%,预后不良 [1]。胆囊癌占所有胆道癌的50%。腺癌占所有胆囊癌的90%~95%,是最常见的亚型,其次是鳞癌、腺鳞癌和神经内分泌癌。胆囊癌男女发病率约为1:3 [2],没有明确的文献表明胆囊结石、胆囊癌与雌、孕激素存在相关性。发病多为50岁以上的肥胖人群。其发病率也在逐年上升。胆囊癌通常转移到肝、肺或淋巴结,但转移到胃肠道并不常见 [3],因此手术治疗效果较差。目前胆囊癌唯一有效的治疗方式为根治性切除联合术后放疗及靶向治疗 [4],近年来,随着外科手术的不断发展联合肿瘤治疗方法的不断完善,胆囊癌预后和生存率有望逐渐升高,疗效更为显著。虽然胆囊癌存在结肠转移,但大多数病例被认为是腹膜播散引起的胃肠道侵犯。胆囊癌因缺乏典型的症状与体征,所以极易漏诊及误诊。我科收治了一例罕见的胆囊癌淋巴液、腹膜种植肠转移病例。可对胆囊癌进展期侵犯多脏器的临床治疗提供临床思路。

2. 病历摘要

患者女,54岁,因“上腹部疼痛1月余”入院。患者入院前1月无明显诱因出现腹痛,位置不固定,为全腹持续性胀痛,以脐周为甚,伴腹胀、食欲减退,无恶心、呕吐、腹泻,无呕血黑便,无牵涉痛及转移痛,无肛门停止排气排便。无畏寒发热,无胸闷、气促、呼吸困难,无心悸、头痛、头晕等特殊不适。遂至当地县医院就诊,完善相关辅助检查,急诊行“腹腔引流术”,引流出乳糜样液体,引流液检验回报后考虑“淋巴管漏”,术后仍出现反复的上腹疼痛。既往体健,无传染病史,无不良嗜好,家族中无类似病史。查体:T:36.0℃,P:80次/分,R:22次/分;BP:118/75 mmHg。腹部平坦,未见明显肠型蠕动波,肚下可见1个约1cm陈旧性戳卡孔,下腹部可见2个2 cm的腹腔引流管口。全腹压痛、反跳痛伴肌紧张,以脐周及下腹部为甚,无液波震颤及震水音,腹部未触及明显包块。肝脾肋下未触及,双肾区无叩击痛,Murphy症阴性。肠鸣音正常,神经系统查体未见异常。影像学检查:术前全腹CT平扫:1) 腹盆腔积液,中下腹肠系膜脂肪间隙密度增高,腹膜炎待排,右侧腹壁间手术瘢痕;2) 肝左叶结节状钙化灶;3) 胆囊壁增厚;4) 双侧肾盂及输尿管起始部扩张、积水,原因?5) 片内:胸腰骶椎及骨盆诸骨多发结节状高密度影,性质?6) 双侧胸腔薄层积液(见图1)。实验室检查:总胆红素:4.1 umol/L,直接胆红素:2.7 umol/L,间接胆红素:1.4 umol/L,碱性磷酸酶:204 U/L,葡萄糖:6.94 mmol/L。余检查及检验结果均未见异常。腹痛考虑为急性腹膜炎。术前诊断:腹痛查因(淋巴管漏?)。于2022年3月24日在全麻下行腹腔镜探查术。进入腹腔中发现组织粘连较重,视野较差,与家属紧急沟通后中转开腹行开腹探查术。术中探查腹腔,见腹腔内大量乳糜样液体与淡血性腹水,吸尽1200 ml腹水后探查大网膜,可见大网膜上大量粟粒样增生结节,质韧,满肠系膜及肠管壁也可见大量粟粒样结节(见图2)。向上探及腹腔,触及质硬胆囊,顺胆囊管走行探及肝门部,质地均硬,考虑为胆囊恶性肿瘤。术中取大网膜予以术中冰冻。术中冰冻结果回示:腺癌(见图3)。术中再次与家属沟通病情,考虑患者已发生淋巴结、腹腔种植转移,预后较差。术中家属商议后,拒绝行胆囊癌根治术,逐层关腹,原位放置2根负压引流管。术后给予护肝、护胃、解痉、补充能量等对症支持治疗。病情稍好转,家属要求自动出院,并签署沟通记录予以出院,叮嘱患者定期返院复查。出院1周后电话随访患者,患者家属诉,患者精神饮食差,引流管仍引流出乳糜样液体及淡血性腹水,较前减少。出院2周后再次电话随访患者,患者家属诉,患者身体状况日渐衰弱,已存在意识模糊,无法进食,持续给予肠外营养支持,引流管间断引流出少许乳糜样液体及血性腹水。出院3周电话随访患者,患者已去世2天,体型消瘦,约35 KG。

(a) (b)(c) (d)(a)、(b):提示胆囊壁增厚;(c)、(d):脊柱多发结节状高密度影,性质待查。

Figure 1. Preoperative CT

图1. 术前CT

Figure 2. A large number of miliary nodules on the surface of greater omentum and mesentery can be seen during operation

图2. 术中可见大网膜、肠系膜表面大量粟粒样结节

(a) (b)

Figure 3. Frozen results during operation. (a): The formation of glandular tubular structure can be seen; (b): A large number of heterotypic cells with large and deeply stained nuclei can be seen

图3. 术中冰冻结果。(a):可见腺管状结构形成;(b):可见大量核大深染的异型性细胞

3. 讨论

胆囊癌在早期很难发现,也较容易转移 [5]。早期无特殊症状,诊断时常常已处于晚期阶段,预后极差,这可能与针对其发病机制的研究尚且不够深入有关。胆囊癌发病率、死亡率较高,其五年生存率仅为19% [6] [7] [8]。平均生存期为3到11个月 [9]。随着医学技术的不断发展,诊断治疗技术也不断在完善,但其预后仍较差主要也归咎于以下两方面,首先诊断较晚,其次是较早发生转移,其最主要转移至肝脏、门静脉淋巴结和骨骼 [10],以及周围毗邻器官。而转移到胃肠道较少。淋巴结转移也是其常见的转移方式,发生率约为47%,肿瘤浸润深度越深,淋巴结转移率更大 [11] [12]。其中,原发灶血行转移及腹膜种植到胃肠道较多见,然而通过淋巴液种植转移腹膜、胃肠道相对罕见。胆囊癌发病部位中,60%发生在胆囊体、30%发生在胆囊底,胆囊颈发病率占10% [13]。胆囊癌最早通过淋巴转移,随着淋巴结不断的转移,导致肿瘤细胞阻塞淋巴管,形成淋巴管漏,会进一步导致腹腔种植转移,因此预后往往很差。胆囊癌缺乏典型的临床表现,最主要的临床表现包括右上腹部反复疼痛、黄疸及肿瘤压迫相关的临床表现,诊断较困难。恶性肿瘤往往侵犯器官本身及相邻组织,如若在肿瘤早期,肿瘤侵犯较浅的组织,影像学较难发现,外加临床症状比较隐匿,更容易误诊及漏诊。胆囊癌不同于其他肿瘤,呈进展性发展,更缺乏相对典型的临床表现。CT检查胆囊癌,其特异性95.6%,灵敏性94.8% [14]。然而PET-CT对所有恶性肿瘤诊断性较高,但其花费较高,很难作为常规检查用于临床。因此诊断更多是需要病理学检查及基因检测技术给予技术指导。胆囊癌的发病机制及危险因素尚不明确。相关危险因素包括胆囊本身的解剖结构、胆囊本身的疾病、胆道疾病、特殊细菌病毒的长期慢性感染 [15],因此要加强其早期干预,防止进一步演变。发病机制还包括当前的研究热点基因突变、免疫检查点的逃逸。胆囊癌的治疗同其他恶性肿瘤相同,尽管治疗仍以手术为主,但新的治疗方式,基于原发性肝癌治疗方式,如区域治疗 [16] 以及基于分子医学的定向治疗,放疗及最新的免疫治疗,已经改善了晚期疾病患者的预后。此例患者因术中发现时病情较晚,已出现广泛转移,家属要求保守治疗,未予以辅助治疗。

综上所述,此患者术前未明确诊断胆囊癌,CT及抽血化验结果均未见异常。按常规急腹症给予腹部探查,根据术中冰冻结果确诊。若临床上遇到类似患者,需要术前完善MRCP及CT平扫 + 增强,需与胆囊常规疾病进行鉴别。

NOTES

*通讯作者Email: 957989114@qq.com

参考文献

[1] Ganeshan, D., Kambadakone, A, Nikolaidis, P., Subbiah, V., Subbiah, I.M. and Devine, C. (2021) Current Update on Gallbladder Carcinoma. Abdominal Radiology, 46, 2474-2489.
https://doi.org/10.1007/s00261-020-02871-2
[2] Roa, J.C., Basturk, O. and Adsay, V. (2021) Dysplasia and Car-cinoma of the Gallbladder: Pathological Evaluation, Sampling, Differential Diagnosis and Clinical Implications. Histo-pathology, 79, 2-19.
https://doi.org/10.1111/his.14360
[3] Sons, H.U., Borchard, F. and Joel, B.S. (1985) Carcinoma of the Gallblad-der: Autopsy Findings in 287 Cases and Review of the Literature. Journal of Surgical Oncology, 28, 199-206.
https://doi.org/10.1002/jso.2930280311
[4] 窦常伟, 张成武. 腹腔镜胆囊癌根治术的临床应用体会及思考[J]. 肝胆胰外科杂志, 2020, 32(5): 270-273, 276.
[5] Peng, H., Fan, K., Zan, R., Gong, Z.J., Sun, W., Sun, Y., Wang, W., Jiang, H., Lou, J., Ni, J., Suo, T. and Zhang, X. (2021) Degradable Magnesium Implants Inhibit Gallbladder Cancer. Acta Biomaterialia, 128, 514-522.
https://doi.org/10.1016/j.actbio.2021.04.051
[6] Henson, D.E., Albores-Saavedra, J. and Code, D. (1992) Carci-noma of the Gallbladder. Histologic Types, Stage of Disease, Grade, and Survival Rates. Cancer, 70, 1493-1497,
https://doi.org/10.1002/1097-0142(19920915)70:6<1493::AID-CNCR2820700608>3.0.CO;2-U
[7] Nimura, Y. (2002) Extended Surgery in Bilio-Pancreatic Cancer: The Japanese Experience. Seminars in Oncology, 29, 17-22.
https://doi.org/10.1016/S0093-7754(02)70022-5
[8] Malenica, I., Donadon, M. and Lleo, A. (2020) Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift towards a Personalized Medicine. Can-cers, 12, Article No. 2190.
https://doi.org/10.3390/cancers12082190
[9] Ausania, F., Tsirlis, T., White, S.A., French, J.J., Jaques, B.C., Charnley, R.M. and Manas, D.M. (2013) Incidental pT2-T3 Gallbladder Cancer after a Cholecystectomy: Outcome of Staging at 3 Months Prior to a Radical Resection. HPB (Oxford), 15, 633-637.
https://doi.org/10.1111/hpb.12032
[10] Tange, S., Hakuta, R., Nakai, Y., Oyama, H., Noguchi, K., Ito, Y., Bae, Y., Kumasaka, T. and Yoshida, H. (2021) A Rare Case of Gallbladder Cancer with Multiple Metastases to the Colon. Clini-cal Journal of Gastroenterology, 14, 608-612.
https://doi.org/10.1007/s12328-020-01301-6
[11] 陈晨, 刘德春, 从龙龙, 等. 基于阳性淋巴结数的进展期胆囊癌患者生存列线图预测模型[J]. 中华肝脏外科手术学电子杂志, 2018, 7(4): 274-279.
[12] Lee, S.E., Kim, K.S., Kim, W.B., et al. (2014) Practical Guidelines for the Surgical Treatment of Gallbladder Cancer. Journal of Korean Medi-cal Science, 29, 1333-1340.
https://doi.org/10.3346/jkms.2014.29.10.1333
[13] 王健东, 全志伟. 胆囊癌的综合治疗[J]. 中华消化外科杂志, 2011, 10(2): 93-95.
[14] 杨庆芬, 郭建. 胆囊癌与慢性胆囊炎的CT鉴别诊断价值[J]. 影像研究与医学应用, 2021, 5(18): 14-15.
[15] 张剑. 胆囊癌发病相关危险因素的研究进展[J]. 现代医药卫生, 2022, 38(1): 85-89.
[16] Llovet, J.M., De Baere, T., Kulik, L., Haber, P.K., Greten, T.F., Meyer, T. and Lencioni, R. (2021) Locoregional Therapies in the Era of Molecular and Immune Treatments for Hepatocellular Carcinoma. Nature Reviews Gastroenterology & Hepatology, 18, 293-313.
https://doi.org/10.1038/s41575-020-00395-0